Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R6MJ
|
|||
| Former ID |
DNCL002636
|
|||
| Drug Name |
MORAb-009
|
|||
| Synonyms |
Amatuximab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163] | Phase 2 | [1], [2] | |
| Company |
Eisai
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | . | [3], [4] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7750). | |||
| REF 2 | ClinicalTrials.gov (NCT00570713) An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. | |||
| REF 4 | National Cancer Institute Drug Dictionary (drug id 543500). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.